[1]王海银孙辉王昊德符雨嫣谢春艳许明飞金春林.价值重塑下的我国卫生技术评估发展与展望[J].中国卫生质量管理,2022,29(06):001-3.[doi:10.13912/j.cnki.chqm.2022.29.6.01 ]
　WANG Haiyin,SUN Hui,WANG Haode.Development and Prospect of Health Technology Assessment in China under the Value Remodeling[J].Chinese Health Quality Management,2022,29(06):001-3.[doi:10.13912/j.cnki.chqm.2022.29.6.01 ]
点击复制

价值重塑下的我国卫生技术评估发展与展望
分享到：

《中国卫生质量管理》[ISSN:1006-7515/CN:CN 61-1283/R]

卷:
第29卷
期数:
2022年06期
页码:
001-3
栏目:
特别关注
出版日期:
2022-06-28

文章信息/Info

Title:
Development and Prospect of Health Technology Assessment in China under the Value Remodeling
作者:
王海银孙辉王昊德符雨嫣谢春艳许明飞金春林
上海市卫生和健康发展研究中心
Author(s):
WANG Haiyin; SUN Hui; WANG Haode
Shanghai Health Development Research Center
关键词:
价值重塑; 价值医疗; 卫生技术评估; 实践; 政策建议
Keywords:
Value Reshaping; Value-Based Health Care;  Health Technology Assessment; Practice; Policy Advice
分类号:
R197.323
DOI:
10.13912/j.cnki.chqm.2022.29.6.01
文献标志码:
A
摘要:
基于价值的医疗服务供给是世界范围内的热点议题。通过系统梳理价值医疗内涵，分析价值重塑下我国卫生技术评估面临的挑战，提出建立科学的HTA运作机制，加强HTA筹资及服务购买机制建设，制定HTA方法指南、加强HTA相关数据库建设等建议，旨在为我国卫生事业高质量发展提供参考。
Abstract:
Value-based medical service supply is a hot issue in the world. By systematically sorting out the connotation of value-based medical treatment, analyzing the challenges of Health Technology Assessment (HTA) in China under the value remodeling, it put forward some suggestions, such as establishing scientific HTA operation mechanism, strengthening the construction of HTA financing and service purchase mechanism, and formulating HTA method guidelines and strengthening the construction of HTA database, in order to provide reference for the high-quality development of health undertakings in China.

参考文献/References:

［1］World Health Orgnization.Weekly epidemiological update on COVID-19 - 5 October 2021［R］.2021. ［2］World Health Orgnization.World health statistics 2021: monitoring health for the SDGs, sustainable development goals［R］. 2021. ［3］陈英耀, 刘文彬, 耿劲松,等.发展我国卫生技术评估的政策建议［J］. 中国卫生质量管理, 2015, 22(1): 61-64. ［4］傅 卫, 赵 琨.中国卫生技术评估的发展与挑战［J］. 卫生经济研究, 2019, 36(3): 3-5. ［5］World Health Orgnization.Strategizing national health in the 21st century: a handbook［R］.2016. ［6］World Health Orgnization.From value for money to value-based health services: a twenty-first century shift［R］.2021. ［7］BADASH I, KLEINMAN NP, BARR S, et al.Redefining health: the evolution of health ideas from antiquity to the era of value-based care［J］. Cureus, 2017, 9(2): e1018. ［8］GENTRY S, BADRINATH P.Defining health in the era of value-based care: lessons from England of relevance to other health systems［J］. Cureus, 2017, 9(3): e1079. ［9］HARRILL WC, MELON DE.A field guide to U.S. healthcare reform: the evolution to value‐based healthcare［J］. Laryngoscope Investigative Otolaryngology, 2021,6(3):590-599. ［10］金春林, 王海银, 孙辉,等.价值医疗的概念、实践及其实现路径［J］. 卫生经济研究, 2019,36(2): 6-8. ［11］World Health Orgnization.2015 global survey on health technology assessment by national authorities［R］.2015. ［12］WANG H, JIN C, Bai F,et al.Driving factors and mode transformation regarding Health Technology Assessment (HTA) in China: problems and recommendations［J］. Biosci Trends, 2019, 13(2): 110-116. ［13］ZHEN X, SUN X, DONG H.Health technology assessment and its use in drug policies in China［J］. Value in Health Regional Issues, 2018, 15: 138-148. ［14］王李婷, 彭六保, 彭 烨,等.2020年版和2011年版中国药物经济学评价指南比较分析［J］. 中国药物经济学, 2021,16(3): 5-8,15. ［15］朱文涛, 高海亮, 卢 颖,等.药物经济学评价报告质量评估指南（PEERs）解读［J］. 中国医疗保险, 2020(6): 68-73. ［16］OCHALEK J, WANG H, Gu Y, et al.Informing a Cost-Effectiveness threshold for health technology assessment in China: a marginal productivity approach［J］. Pharmaco Economics, 2020, 38(12): 1319-1331. ［17］WU J, XIE S, HE X, et al.Valuation of SF-6Dv2 health states in China using time trade-off and Discrete-Choice experiment with a duration dimension［J］. Pharmaco Economics, 2021, 39(5): 521-535. ［18］WU J, XIE S, HE X. et al.The simplified Chinese version of SF-6Dv2: translation, cross-cultural adaptation and preliminary psychometric testing［J］. Qualityof Life Research: an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 2020, 29(5): 1385-1391. ［19］王海银, 符雨嫣, 覃肖潇，等.药品临床综合评价：保障临床基本用药合理使用［J］. 中国卫生, 2021(8): 72-73. ［20］蔡 俊, 龚瑞雪, 李丹滢，等.国内卫生技术评估的文献计量分析［J］. 临床药物治疗杂志, 2021，19(3): 77-80. ［21］王晓静, 于 挺, 包 晗.近十年国内外卫生技术评估研究热点和前沿［J］. 现代医院管理, 2021，19(4): 17-22. ［22］KIM H, GOODALL S, LIEW D.Health technology assessment challenges in oncology: 20 years of value in health［J］. Value in Health:the Journal of the International Society for Pharmacoeconomics and Outcomes Research, 2019, 22(5): 593-600. ［23］PHILLIPS KA, DEVERKA PA, MARSHALL DA, et al.Methodological issues in assessing the economic value of Next-Generation Sequencing tests: many challenges and not enough solutions［J］. Value in Health:the Journal of the International Society for Pharmacoeconomics and Outcomes Research,2018, 21(9): 1033-1042. ［24］VUKOVIC V, FAVARETTI C, RICCIARDI W, et al.Health technology assessment evidence on e-health/m-health technologies: evaluating the transparency and thoroughness［J］. International Journal Technology Assessment in Health Care, 2018, 34(1): 87-96. ［25］NOVES HM, SOAREZ PC. Health Technology Assessment (HTA) organizations: dimensions of the institutional and political framework［J］. Cadernos de Saude Publica,2016,32(Suppl 2):e000 22315.

相似文献/References:

[1]徐肖楠 吕娜 朱腾 杨素玲 田苗 王华芬.基于价值医疗的制度精细化管理[J].中国卫生质量管理,2020,27(01):025.[doi:10.13912/j.cnki.chqm.2020.27.1.06]

更新日期/Last Update: 2022-06-28